Antibody Design and Conjugation

Creative Biolabs has over a decade of working experience in antibody design and modification to fit various bio-conjugation strategies, especially for the development of antibody-drug conjugates (ADCs).

As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse conjugation chemistry. Multiple endogenous amino acids can serve as potential conjugation sites. However, to achieve more precisely controlled site-directed conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR), special moieties with unique conjugation chemistries are engineered into antibody sequences in our antibody design services.

Antibody Design and Conjugation Some endogenous or engineered sites for the conjugation of cytotoxic payload drugs to an antibody (Antibodies,2015).

To retain antibody bioactivity, mild, near-physiological conditions are often used for conjugation reactions. Under these conditions, endogenous amino acids such as Lys and Cys are chemically reactive and can be used as conjugation sites. Scientists at Creative Biolabs are experienced in performing Lysine conjugation (amine reaction) as well as Cysteine conjugation (thiol reactions) to create ADCs using these endogenous sites. We are also expertise in exploiting Tyrosine conjugation approaches as another innovated endogens site for ADC development.

One downside in using the endogenous amino acids for ADC development is a heavily dispersed drug-to-antibody ratio (DAR) caused by the non-uniform distribution of the conjugation sites, especially in the case of Lysine-based conjugations. To achieve a narrower DAR, Creative Biolabs has explored and adopted a variety of methodologies in antibody design and engineering to introduce a series of specific and chemically versatile conjugation sites into the antibody sequences:

  • We incorporate Cysteine residues into defined sites on an antibody to create thiol-engineered antibody (EnCys-mAb) and conjugate payload drugs onto those Cysteine residues via thiol-based chemistry.
  • Unnatural amino acids (UAAs), such as p-Acetyl Phenylalanine, are integrated into antibody sequences via amber stop codon-mediated transcription and their chemically diverse side chains are excellent sites to introduce the payload drug for ADC preparation.
  • Some enzymes, such as Sortase A, transglutaminases, formylglycin generating enzyme…, recognize and modify certain amino acids on a peptide motif to yield chemically activated side chains. Creative Biolabs exploits these approaches and developed Enzyme-mediated modification and conjugation system to help generate ADCs with specific conjugation sites.
  • Through antibody design, we create a “cave” on the desired locations on an antibody to facilitate meditope trapping and subsequently, achieve site-specific meditope-based conjugations.
  • We take advantage of the self-splicing inteins and engineer intein-fusion antibodies, thereby achieving C-terminal specific antibody modification and yielding conjugates with DARs at 1 or 2.

Alongside the efforts of antibody engineering, we also apply several enzymatic or physical approaches to afford site-specific antibody-drug conjugations by modifying the carbohydrate moiety via galactosidases and galactosyltransferases or photo-crosslinking indole-3-butyric acid containing linkers onto antibody nucleotide binding site.

Engineered/non-engineered antibodies are conjugated to the corresponding drug-linker set designed and prepared in DrugLnk and purified via suitable liquid chromatography techniques. The resulted ADCs are characterized for some basic biochemical parameters such as DAR, stability, conjugation site distribution….

Designing a chemically compatible antibody for the conjugation chemistry is a key step that directly dictates the fate of an ADC project. With expertise and dedication, advanced antibody design platform and services from Creative Biolabs will be your best companion in creating customized ADCs. Please contact us for more information and a detailed quote.


  1. Dennler, P.; et al. Antibody conjugates: from heterogeneous populations to defined reagents. Antibodies. 2015, 4: 197-224.

Case Study

For Research Use Only. NOT FOR CLINICAL USE.

Related Sections

Online Inquiry
*E-mail Address:
*Products or Services Interested:
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us